AsiaNet-Pakistan Premier Editorial Content and Press Release Distribution Service
Karachi: Abbott Laboratories (Pakistan) Limited has released its unaudited condensed interim financial statements for the six months and second quarter ended June 30, 2024. The Directors highlighted significant improvements in sales and profitability across all segments, marking a turnaround from the previous year’s losses.
According to information available from the Pakistan Stock Exchange (PSX), overall sales for the first half of 2024 grew by 18% compared to the same period last year. The pharmaceutical segment saw a 17% increase, driven by the strong performance of established brands. The diagnostics division experienced a remarkable 38% growth due to new customer acquisitions, while nutritional sales rose by 13%.
Gross profit margin for the company improved substantially during this period, reaching 26% compared to 21% in the previous year. This improvement was attributed to strategic price adjustments and efficiency measures. Specifically, the pharmaceutical sector’s gross margin rose to 26% from 23%, and the nutritional segment’s margin increased significantly to 32% from 23%.
Administrative and selling expenses also saw increases of 8% and 14% respectively, aligned with inflation and sales growth. Nevertheless, net profit as a percentage of sales improved dramatically to 7%, compared to a net loss of 3% in the same period last year.
For the second quarter alone, sales escalated by 20% year-over-year, with pharmaceuticals up by 18% and nutrition by 25%, primarily due to pricing adjustments. Gross profit margin for the quarter also improved, reaching 24% from 19% the previous year. Other charges, including statutory fees, surged by 53% due to higher profitability.
Looking forward, Abbott Laboratories Pakistan remains cautiously optimistic. The recent stability in exchange rates and inflation has alleviated some pressure on the pharmaceutical sector, though the overall economic outlook remains mixed. The company emphasized the importance of sustained economic stability and supportive fiscal policies, along with regulatory reforms, to maintain industry growth.
Despite potential challenges, Abbott Laboratories Pakistan is committed to enhancing productivity and implementing cost containment measures to mitigate adverse impacts and sustain its growth trajectory.
The post Abbott Laboratories Pakistan Reports Robust Growth and Profit Recovery in First Half of 2024 appeared first on .